BioSpace News Archive

Following months of collaborative development work, Aerogen® and CanSinoBIO have announced a development and commercial supply partnership for the inhaled delivery of CanSinoBIO’s Recombinant Novel Coronavirus Vaccine Convidecia™ utilizing Aerogen’s proprietary vibrating mesh aerosol drug delivery technology.

iOnctura SA, a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, is presenting clinical data on its lead pipeline asset, the PI3Kδ inhibitor IOA-244, showing no dose-limiting toxicity and a reduction in T regulatory cells.

CANbridge Pharmaceuticals, Inc. announced that it signed the collaboration on a rare disease research agreement with the Peking Union Medical College Hospital, on December 9, 2021.

Amsterdam, the Netherlands – Royal Philips, a global leader in health technology, expanded its ultrasound portfolio with new robust imaging tools and features for Cardiology to increase diagnostic confidence and workflow efficiency.

SQZ Biotechnologies Company (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today presented interim results from the highest-dose cohort of its ongoing Phase 1/2 clinical trial of lead Antigen Presenting Cell (APC) therapy candidate targeting Human Papillomavirus positive (HPV16+) solid tumors at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress.

Sun Nuclear Corporation, a wholly-owned subsidiary of Mirion Technologies, Inc., announced that Allegheny Health Network, a Highmark Health Company, has selected Sun Nuclear as its radiation therapy Quality Assurance solutions partner.

Identifying GP2 specific T cell immune response at baseline prior to treatment with GP2 has potential to predict breast cancer recurrence risk and timing of recurrence.

KalVista Pharmaceuticals, Inc. today provided an operational update and released financial results for the second fiscal quarter ended October 31, 2021.

SparingVision announces the appointment of Dr Mehdi Gasmi, PhD, as Chief Operating Officer, as well as other senior appointments, further strengthening the SparingVision team.

Intercept Pharmaceuticals, Inc. today announced that it has formally notified the European Medicines Agency (EMA) of its decision to withdraw its Marketing Authorization Application (MAA) for obeticholic acid (OCA) for the treatment of liver fibrosis.